Home > Cardiology > ACC 2021 > COVID-19 > Atorvastatin does not reduce mortality in COVID-19

Atorvastatin does not reduce mortality in COVID-19

Presented By
Dr Behnood Bikdeli, Yale University School of Medicine, USA
Conference
ACC 2021
Trial
INSPIRATION
Patients who were hospitalised with COVID-19 and given atorvastatin fared no better than patients who were given a placebo, with respect to reducing venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation (ECMO), or all-cause mortality [1]. Results of the INSPIRATION trial also found no difference between the groups in terms of the main safety outcomes of clinically diagnosed myopathy or elevated liver enzymes. Some patients with COVID-19 exhibit a dramatic immune response, resulting in increased thrombotic events and a hyperinflammatory state. The intensity of the immune response can lead to the development of acute respiratory distress syndrome (ARDS) and ultimately death. Statins are known to have pleiotropic effects that include both anti-inflammatory and anti-thrombotic effects. Previous studies have shown a beneficial effect of statins on hyper-inflammatory phenotypes of ARDS (but not hypo-inflammatory phenotypes) [2,3]. Fur...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on